Affluent Medical

Climate Impact & Sustainability Data (2021)

Medium-term Goals:

Short-term Goals:

Covid-19 pandemic impact on clinical trials (delays in patient recruitment, obtaining authorisations, supply chain disruptions)
Competition from larger companies with greater resources and experience
Risks related to obtaining and maintaining marketing authorisations
Intellectual property rights challenges
Pricing and reimbursement policy uncertainties
Product liability risks
Industrialisation challenges (manufacturing processes, quality control)
Dependence on third-parties (suppliers, subcontractors)
Implementation of marketing strategy
Maintaining collaboration agreements
Dependence on qualified personnel and key executives
Liquidity risk
Insurance coverage costs
Dilution risk from share issuances
Access to public subsidies and funding
Past and future losses
Depreciation of intangible assets

Regular discussions with partners, service providers, and suppliers to mitigate Covid-19 impacts
Diversification strategy (three implants and licensing of Kardiozis technology)
Rigorous procedures with manufacturing subcontractors
Dual organisation with proprietary production and subcontracting
Hybrid commercial strategy (direct and indirect sales)
Policy to retain key personnel
Actively studying various financing solutions
Implementing a policy to cover primary insurable risks
Seeking public aid and funding
Conducting medico-economic studies to support reimbursement
Strengthening relationships with private insurers

Qualification of suppliers according to quality standards (ISO 13485:2016, ISO 9001:2015, ISO 11135:2014, ISO 17025:2017)
Annual evaluation of suppliers
Regular audits by the quality department

Frameworks Used: IFRS

Certifications: ISO 13485:2016